Impact of Market Authorization Holder (MAH) system on pharmaceutical innovation in China
The findings suggest that the MAH system significantly enhances pharmaceutical innovation. Management incentives strengthen this effect, while financing constraints serve as an intermediary. The MAH system effectively stimulates innovation in the pharmaceutical industry, with management incentives playing a critical moderating role.
Authors
- Suodi Zhai (ORCID: https://orcid.org/0000-0003-2220-359X)
- Ruining Zhang
- Li Yang (ORCID: https://orcid.org/0000-0003-0640-2003)
- Ruiying Han
- Yao Lv (ORCID: https://orcid.org/0000-0001-9434-9665)
- Quan Wang (ORCID: https://orcid.org/0000-0003-3501-9513)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-9586-595X)
- Zheng Zhu (ORCID: https://orcid.org/0000-0002-5246-3758)
- Chao hua Zhu
Institutions
- Johns Hopkins University (US)
- National University of Singapore (SG)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Peking Union Medical College Hospital (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- National University Health System (SG)
Publication Details
- Journal
- Journal of Pharmaceutical Policy and Practice
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1080/20523211.2025.2551794
- Primary Topic
- Innovation Policy and R&D
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China